In wet AMD, RPE is a key player to produce angiogenic compounds, including vascular endothelial growth factor (VEGF), which is targeted by specific antibodies or fusion proteins in the therapy of this AMD form. This evidence concerns the gene VEGFA and wet macular degeneration.